Menopausal Osteoporosis

Musculoskeletal·MeSH: Osteoporosis, Postmenopausal

Prevalence

7000.0 / 100K

Incidence

300.0 / 100K/yr

11 drugs in development·4 companies·1 clinical trial

Drug Pipeline by Phase

Approved(1)

Drug	Company
calcitonin-salmon	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(4)

Drug	Company
ENZ215	Crinetics Pharmaceuticals, Inc. (CRNX)
ENZ215	ENANTA PHARMACEUTICALS INC (ENTA)
Prolia	ENANTA PHARMACEUTICALS INC (ENTA)
Prolia	Crinetics Pharmaceuticals, Inc. (CRNX)

Phase 2(5)

Drug	Company
Estradiol	Cidara Therapeutics, Inc. (CDTX)
Testosterone	ENANTA PHARMACEUTICALS INC (ENTA)
Testosterone	Cidara Therapeutics, Inc. (CDTX)
Triptorelin 11.25 mg	ENANTA PHARMACEUTICALS INC (ENTA)
Triptorelin 11.25 mg	Cidara Therapeutics, Inc. (CDTX)

Phase 4(1)

Drug	Company
Sodium Chloride 0.9%	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 11 drugs in development for Menopausal Osteoporosis across 4 companies.

There are 1 clinical trial targeting Menopausal Osteoporosis tracked by BioSniper.

The estimated prevalence of Menopausal Osteoporosis is approximately 7000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.